Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glaxo SmithKline

- PMLiVE

Neupogen will be first biologic on FDA biosimilars pathway

US regulator will review Novartis’  version of Amgen's Neupogen (filgrastim) over the coming months

- PMLiVE

Celgene’s cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

Allergan logo

Allergan wields axe to fend off Valeant

Plans to cut 1.500 jobs in sign of independence

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

Novartis building

Novartis’ vaccine sales decline ahead of GSK transfer

Only business not to show growth during second quarter of 2014

- PMLiVE

GSK trial throws everything at COPD

Tests combination of fluticasone furoate, umeclidinium and vilanterol

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Novartis buys rights to Google’s ‘smart lens’ technology

Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia

- PMLiVE

AbbVie coaxes Shire into discussions with sweetened offer

Raises takeover bid to $53bn

Baxter reshuffles financial heads

Names CFOs for biotech spin-off and 'new' Baxter

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis

Data reinforces secukinumab's position among new generation of biologic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links